Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Sattva S Neelapu
Phase II Study of an AKT Inhibitor MK2206 in Patients With Relapsed or Refractory Lymphoma
Blood
Biochemistry
Immunology
Cell Biology
Hematology
Related publications
Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Interim Update From a Phase 2 Multicenter Study of Tazemetostat, an Ezh2 Inhibitor, in Patients With Relapsed or Refractory Follicular Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Phase II Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Phase 1 Study of the Protein Deubiquitinase Inhibitor VLX1570 in Patients With Relapsed and/or Refractory Multiple Myeloma
Investigational New Drugs
Oncology
Pharmacology
Copanlisib Treatment of Patients With Relapsed or Refractory Marginal Zone Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Phase Ib/Ii Study of Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
A Single Center Phase II Study of Ixazomib in Patients With Relapsed or Refractory Cutaneous or Peripheral T-Cell Lymphomas
American Journal of Hematology
Hematology
Phase II Open Label Study of the Oral Vascular Endothelial Growth Factor-Receptor Inhibitor PTK787/ZK222584 (Vatalanib) in Adult Patients With Refractory or Relapsed Diffuse Large B-Cell Lymphoma
Leukemia and Lymphoma
Cancer Research
Oncology
Hematology
A Phase II Study of Docetaxel in Patients With Relapsed and Refractory Ewing's Tumours
Sarcoma
Nuclear Medicine
Radiology
Imaging
Oncology
